|
US20040082509A1
(en)
|
1999-10-12 |
2004-04-29 |
Christophe Bonny |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
US20090118139A1
(en)
*
|
2000-11-07 |
2009-05-07 |
Caliper Life Sciences, Inc. |
Microfluidic method and system for enzyme inhibition activity screening
|
|
BR0212760A
(pt)
|
2001-09-19 |
2004-12-07 |
Aventis Pharma Sa |
Compostos quìmicos
|
|
US20040087642A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
|
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
|
FR2857362B1
(fr)
*
|
2003-07-10 |
2005-09-23 |
Aventis Pharma Sa |
Tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees, compositions les contenant et utilisation
|
|
GB0324159D0
(en)
|
2003-10-15 |
2003-11-19 |
Glaxo Group Ltd |
Novel compounds
|
|
MY143225A
(en)
|
2004-04-02 |
2011-03-31 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
|
MY139689A
(en)
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
|
US7803824B2
(en)
|
2004-10-29 |
2010-09-28 |
Alcon, Inc. |
Use of inhibitors of Jun N-terminal kinases to treat glaucoma
|
|
US20060094753A1
(en)
|
2004-10-29 |
2006-05-04 |
Alcon, Inc. |
Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
|
|
CN101212967A
(zh)
|
2005-05-10 |
2008-07-02 |
因塞特公司 |
吲哚胺2,3-双加氧酶调节剂及其用法
|
|
WO2007031098A1
(en)
|
2005-09-12 |
2007-03-22 |
Xigen S.A. |
Cell-permeable peptide inhibitors of the jnk signal transduction pathway
|
|
CA2623125A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP2270014A1
(en)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
|
UA116187C2
(uk)
|
2005-12-13 |
2018-02-26 |
Інсайт Холдінгс Корпорейшн |
ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
|
|
DE102006049452A1
(de)
|
2006-10-17 |
2008-05-08 |
Grünenthal GmbH |
Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
|
|
EP2121692B1
(en)
|
2006-12-22 |
2013-04-10 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
|
WO2008157208A2
(en)
|
2007-06-13 |
2008-12-24 |
Incyte Corporation |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
CA2697941A1
(en)
*
|
2007-09-06 |
2009-03-12 |
Glaxo Group Limited |
Piperazine derivative having affinity for the histamine h3 receptor
|
|
US8309718B2
(en)
|
2007-11-16 |
2012-11-13 |
Incyte Corporation |
4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
|
ES2387707T3
(es)
*
|
2007-12-21 |
2012-09-28 |
Genentech, Inc. |
Azaindolizinas y procedimientos de uso
|
|
NZ587928A
(en)
|
2008-03-11 |
2012-08-31 |
Incyte Corp |
Azetidine and cyclobutane derivatives as jak inhibitors
|
|
US8871753B2
(en)
|
2008-04-24 |
2014-10-28 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
DE102008022657A1
(de)
*
|
2008-05-07 |
2009-11-19 |
Knorr-Bremse Systeme für Nutzfahrzeuge GmbH |
Achsaggregat und Lenker
|
|
WO2009143864A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
|
|
WO2009143865A1
(en)
*
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
|
CN104042611B
(zh)
|
2008-07-08 |
2019-05-14 |
因塞特控股公司 |
作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑
|
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
US8710104B2
(en)
|
2008-11-07 |
2014-04-29 |
Triact Therapeutics, Inc. |
Catecholic butanes and use thereof for cancer therapy
|
|
WO2010068520A2
(en)
*
|
2008-12-11 |
2010-06-17 |
Cara Therapeutics, Inc. |
Substituted imidazoheterocycle derivatives
|
|
WO2010072228A1
(en)
|
2008-12-22 |
2010-07-01 |
Xigen S.A. |
Novel transporter constructs and transporter cargo conjugate molecules
|
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
KR20120020099A
(ko)
|
2009-04-20 |
2012-03-07 |
오에스아이 파마슈티컬스, 엘엘씨 |
Ｃ-피라진-메틸아민의 제조
|
|
PE20120371A1
(es)
|
2009-05-22 |
2012-05-17 |
Incyte Corp |
3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
|
|
EP2432555B1
(en)
|
2009-05-22 |
2014-04-30 |
Incyte Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
PL2448938T3
(pl)
|
2009-06-29 |
2014-11-28 |
Incyte Holdings Corp |
Pirymidynony jako inhibitory PI3K
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
MX2012004180A
(es)
|
2009-10-09 |
2012-07-17 |
Incyte Corp |
Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo.
|
|
TW201130842A
(en)
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
|
US20110207754A1
(en)
|
2010-02-18 |
2011-08-25 |
Incyte Corporation |
Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
|
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP2519826A2
(en)
|
2010-03-03 |
2012-11-07 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
US20130005733A1
(en)
|
2010-03-09 |
2013-01-03 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
DK3354652T3
(da)
|
2010-03-10 |
2020-05-18 |
Incyte Holdings Corp |
Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
|
|
CA2796311A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
Fused derivatives as pi3k.delta. inhibitors
|
|
PE20130216A1
(es)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
Formulacion topica para un inhibidor de jak
|
|
FR2960876B1
(fr)
*
|
2010-06-03 |
2012-07-27 |
Sanofi Aventis |
Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
|
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
|
WO2011160653A1
(en)
|
2010-06-21 |
2011-12-29 |
Xigen S.A. |
Novel jnk inhibitor molecules
|
|
CA2807036C
(en)
|
2010-10-14 |
2018-01-16 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
|
|
EP2640725B1
(en)
|
2010-11-19 |
2015-01-07 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
PH12013501001A1
(en)
|
2010-11-19 |
2019-09-02 |
Incyte Holdings Corp |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
CA2822070C
(en)
|
2010-12-20 |
2019-09-17 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
|
CN103732226B
(zh)
|
2011-02-18 |
2016-01-06 |
诺瓦提斯药物公司 |
mTOR/JAK抑制剂组合疗法
|
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
AR086983A1
(es)
|
2011-06-20 |
2014-02-05 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
|
CA2844507A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
Jak pi3k/mtor combination therapy
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
PH12021552978A1
(en)
|
2011-09-02 |
2022-08-22 |
Incyte Holdings Corp |
Heterocyclylamines as pi3k inhibitors
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
WO2013091670A1
(en)
|
2011-12-21 |
2013-06-27 |
Xigen S.A. |
Novel jnk inhibitor molecules for treatment of various diseases
|
|
FR2986002B1
(fr)
*
|
2012-01-24 |
2014-02-21 |
Servier Lab |
Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
AR091079A1
(es)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
|
|
EP3495367B1
(en)
|
2012-06-13 |
2020-09-30 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
AR093308A1
(es)
|
2012-11-01 |
2015-05-27 |
Incyte Corp |
Derivados triciclicos fusionados de tiofeno como inhibidores de jak
|
|
NZ708157A
(en)
|
2012-11-15 |
2019-07-26 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
US9834575B2
(en)
|
2013-02-26 |
2017-12-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
TW202214254A
(zh)
|
2013-03-01 |
2022-04-16 |
美商英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
|
|
SMT201900081T1
(it)
|
2013-03-06 |
2019-05-10 |
Incyte Holdings Corp |
Procedimenti e intermedi per produrre un inibitore di jak
|
|
DK2986610T5
(en)
|
2013-04-19 |
2018-12-10 |
Incyte Holdings Corp |
BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|
|
PE20200527A1
(es)
|
2013-05-17 |
2020-03-09 |
Incyte Corp |
Derivados del bipirazol como inhibidores jak
|
|
CA2903275A1
(en)
|
2013-06-26 |
2014-12-31 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
|
WO2015197097A1
(en)
|
2014-06-26 |
2015-12-30 |
Xigen Inflammation Ltd. |
New use for jnk inhibitor molecules for treatment of various diseases
|
|
WO2014206427A1
(en)
|
2013-06-26 |
2014-12-31 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
|
FR3008976A1
(fr)
*
|
2013-07-23 |
2015-01-30 |
Servier Lab |
"nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
|
|
HRP20200955T1
(hr)
|
2013-08-07 |
2020-10-02 |
Incyte Corporation |
Dozni oblici s produženim oslobađanjem za jak1 inhibitor
|
|
JP2016528288A
(ja)
|
2013-08-20 |
2016-09-15 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
上昇したｃ反応性タンパク質レベルを有する固形腫瘍の患者における延命効果
|
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
|
TW201605859A
(zh)
*
|
2013-11-14 |
2016-02-16 |
必治妥美雅史谷比公司 |
作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌
|
|
US10787410B2
(en)
|
2013-12-16 |
2020-09-29 |
The Johns Hopkins University |
Treating and preventing diseases by modulating cell mechanics
|
|
KR20160136323A
(ko)
|
2014-02-28 |
2016-11-29 |
인사이트 코포레이션 |
골수형성이상증후군 치료용 jak1 억제제
|
|
MX368767B
(es)
*
|
2014-04-07 |
2019-10-15 |
Netherlands Translational Res Center B V |
(5,6-dihidro)pirimido[4,5-e]indolizinas.
|
|
NZ763326A
(en)
|
2014-04-08 |
2023-04-28 |
Incyte Holdings Corp |
Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
|
|
PE20170300A1
(es)
|
2014-04-30 |
2017-04-19 |
Incyte Corp |
Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
|
WO2016130501A1
(en)
|
2015-02-09 |
2016-08-18 |
Incyte Corporation |
Aza-heteroaryl compounds as pi3k-gamma inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
CR20170390A
(es)
|
2015-02-20 |
2017-10-23 |
Incyte Holdings Corp |
Heterociclos biciclicos como inhibidores de fgfr
|
|
LT3262046T
(lt)
|
2015-02-27 |
2021-01-11 |
Incyte Corporation |
Pi3k inhibitoriaus druskos ir jų gamybos būdai
|
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
WO2016183062A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
|
PT3371190T
(pt)
|
2015-11-06 |
2022-07-08 |
Incyte Corp |
Compostos heterocíclicos como inibidores de pi3k-gamma
|
|
US20170190689A1
(en)
|
2016-01-05 |
2017-07-06 |
Incyte Corporation |
Pyridine and pyridimine compounds as pi3k-gamma inhibitors
|
|
CN105646495A
(zh)
*
|
2016-01-06 |
2016-06-08 |
中山大学 |
一种吡咯并[2,3-b]吡嗪衍生物及其制备方法和应用
|
|
EP3203509B1
(en)
|
2016-02-04 |
2021-01-20 |
Services Pétroliers Schlumberger |
Double-sided hermetic multichip module
|
|
TW201803871A
(zh)
|
2016-06-24 |
2018-02-01 |
英塞特公司 |
作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
WO2019020070A1
(zh)
*
|
2017-07-27 |
2019-01-31 |
江苏恒瑞医药股份有限公司 |
哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用
|
|
CN118063470A
(zh)
|
2017-10-18 |
2024-05-24 |
因赛特公司 |
作为PI3K-γ抑制剂的由叔羟基取代的缩合咪唑衍生物
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
WO2019126505A1
(en)
|
2017-12-21 |
2019-06-27 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
|
|
IL276302B2
(en)
|
2018-01-30 |
2023-11-01 |
Incyte Corp |
Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one)
|
|
KR20240157777A
(ko)
|
2018-02-16 |
2024-11-01 |
인사이트 코포레이션 |
사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
|
|
CA3092470A1
(en)
|
2018-02-27 |
2019-09-06 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
|
PE20251292A1
(es)
|
2018-03-08 |
2025-05-14 |
Incyte Corp |
Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma
|
|
EP4424328A3
(en)
|
2018-03-30 |
2024-12-04 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
|
CN112566912A
(zh)
|
2018-05-04 |
2021-03-26 |
因赛特公司 |
Fgfr抑制剂的盐
|
|
US11466004B2
(en)
|
2018-05-04 |
2022-10-11 |
Incyte Corporation |
Solid forms of an FGFR inhibitor and processes for preparing the same
|
|
WO2019222677A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
WO2019227007A1
(en)
|
2018-05-25 |
2019-11-28 |
Incyte Corporation |
Tricyclic heterocyclic compounds as sting activators
|
|
CA3101323A1
(en)
|
2018-06-01 |
2019-12-05 |
Incyte Corporation |
Dosing regimen for the treatment of pi3k related disorders
|
|
WO2020010003A1
(en)
|
2018-07-02 |
2020-01-09 |
Incyte Corporation |
AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
US11008344B2
(en)
|
2018-07-31 |
2021-05-18 |
Incyte Corporation |
Tricyclic heteroaryl compounds as STING activators
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
|
US11078204B2
(en)
|
2018-11-13 |
2021-08-03 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
|
WO2020146237A1
(en)
|
2019-01-07 |
2020-07-16 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
MA54947A
(fr)
|
2019-02-15 |
2021-12-22 |
Incyte Corp |
Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
EP3982971A4
(en)
|
2019-06-10 |
2023-08-16 |
Incyte Corporation |
Topical treatment of vitiligo by a jak inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN114502196A
(zh)
|
2019-08-01 |
2022-05-13 |
因赛特公司 |
Ido抑制剂的给药方案
|
|
PH12022550361A1
(en)
|
2019-08-14 |
2023-02-27 |
Incyte Corp |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
US20210061809A1
(en)
|
2019-08-26 |
2021-03-04 |
Incyte Corporation |
Triazolopyrimidines as a2a / a2b inhibitors
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MX2022004390A
(es)
|
2019-10-11 |
2022-08-08 |
Incyte Corp |
Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
|
|
GEAP202415945A
(en)
|
2019-10-14 |
2024-04-25 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11992490B2
(en)
|
2019-10-16 |
2024-05-28 |
Incyte Corporation |
Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
|
|
JP7518900B2
(ja)
|
2019-10-16 |
2024-07-18 |
インサイト・コーポレイション |
皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
AU2021230385A1
(en)
|
2020-03-06 |
2022-09-22 |
Incyte Corporation |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|
|
EP4135844A1
(en)
|
2020-04-16 |
2023-02-22 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
BR112022024632A2
(pt)
|
2020-06-02 |
2023-02-28 |
Incyte Corp |
Processos para preparar um inibidor de jak1
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
|
EP4213800A1
(en)
|
2020-09-16 |
2023-07-26 |
Incyte Corporation |
Topical treatment of vitiligo
|
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
|
US11957661B2
(en)
|
2020-12-08 |
2024-04-16 |
Incyte Corporation |
JAK1 pathway inhibitors for the treatment of vitiligo
|
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
CA3219092A1
(en)
|
2021-05-03 |
2022-11-10 |
Incyte Corporation |
Jak1 pathway inhibitors for the treatment of prurigo nodularis
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
US12441727B2
(en)
|
2021-07-07 |
2025-10-14 |
Incyte Corporation |
Tricyclic compounds as inhibitors of KRAS
|
|
CA3224841A1
(en)
|
2021-07-14 |
2023-01-19 |
Zhenwu Li |
Tricyclic compounds as inhibitors of kras
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
PE20242113A1
(es)
|
2021-10-14 |
2024-10-28 |
Incyte Corp |
Compuestos de quinolina como inhibidores de kras
|
|
WO2023091746A1
(en)
|
2021-11-22 |
2023-05-25 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
|
TW202329937A
(zh)
|
2021-12-03 |
2023-08-01 |
美商英塞特公司 |
雙環胺ｃｋ１２抑制劑
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023122134A1
(en)
|
2021-12-22 |
2023-06-29 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
|
TW202341982A
(zh)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Ｃｄｋ２抑制劑及其用途
|
|
AU2023232823A1
(en)
|
2022-03-07 |
2024-09-12 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
|
EP4540252A1
(en)
|
2022-06-14 |
2025-04-23 |
Incyte Corporation |
Solid forms of a jak inhibitor and process of preparing the same
|
|
US20250353842A1
(en)
|
2022-06-22 |
2025-11-20 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
EP4565229A1
(en)
|
2022-08-05 |
2025-06-11 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|
|
US20240368156A1
(en)
|
2023-04-18 |
2024-11-07 |
Incyte Corporation |
2-azabicyclo[2.2.1]heptane kras inhibitors
|
|
US20240390340A1
(en)
|
2023-04-18 |
2024-11-28 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
US20250163079A1
(en)
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
|
US20250195536A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|